The European Commission has approved, under the EU Merger Regulation, the acquisition of joint control over Oftalmología Vistahermosa, S.L. (‘Oftalvist’) by Clínica Vistahermosa Grupo HLA, S.L.U. (‘HLA Vistahermosa’) and Sanoptis España, S.L.U. (‘Sanoptis’), all of Spain.
The transaction relates primarily to ophthalmology services and private health insurance.
The Commission concluded that the notified transaction would not raise competition concerns, given that the joint venture has negligible activities in the European Economic Area and the companies’ limited combined market position resulting from the proposed transaction. The notified transaction was examined under the simplified merger review procedure.
